SRZN PRESS-RELEASE SEC Filing Analysis

Latest settled — T+20d ⚠ clustered

SRZN ▲ +32.12% at T+20d

NEUTRAL call ✓ call won +32.12% · α vs SPY +23.22% · entry $25.00 → $33.03

Next anchor: T+60d in 7d

Last close $20.69 (close Jun 8) · -17.24% from $25.00 entry

Entry anchored
Mar 23, 03:59 PM ET
via Databento tick

T+1d

+4.56%

call +4.56% · α +3.99%

$26.14

settled 3mo ago

T+5d

+16.52%

call +16.52% · α +16.94%

$29.13

settled 2mo ago

T+20d

+32.12%

call +32.12% · α +23.22%

$33.03

settled 7w ago

T+60d

—

call — · α —

—

in 7d

Price Chart

Loading chart...

Executive Summary

Surrozen reported its 2025 financial results, showing a significant increase in net loss to $242.0 million due to non-cash charges related to its 2025 private placement, despite progress in its ophthalmology pipeline. The company received a $5.0 million milestone payment from Boehringer Ingelheim and ended the year with $89.2 million in cash. It plans to submit an IND for SZN-8141 in late 2026.

Key Financial Metrics

Revenue

$3.5M

-67.3% YoY

EPS

$-32.37

Deal Value

$5.0M

Actionable Insight

The sharp increase in net loss is not reflective of operational deterioration but rather accounting impacts from financing. The $89.2M cash position provides runway, and the $5M milestone from Boehringer Ingelheim validates pipeline progress. Watch for IND submission for SZN-8141 in H2 2026 as the next key catalyst.

Key Facts

Net loss for 2025 was $242.0 million, up from $63.6 million in 2024, primarily due to non-cash losses from the 2025 PIPE financing.
Cash and cash equivalents increased to $89.2 million as of December 31, 2025, from $34.6 million a year earlier, bolstered by $26.9 million in ATM sales and $3.3 million from warrant exercises in early 2026.
Received $5.0 million milestone payment from Boehringer Ingelheim in March 2026 for SZN-413 research achievement.
No collaboration and license revenue in 2025, down from $10.0 million in 2024.
Research service revenue from a related party was $3.5 million in 2025, but the collaboration ended in November 2025.
On track to submit an IND for SZN-8141 in the second half of 2026.

Financial Impact

Net loss increased by $178.4 million YoY, but largely driven by non-cash charges ($71.1M + $104.8M = $175.9M) related to the 2025 PIPE. Core R&D and G&A expenses increased moderately to $45.6M from $36.2M.

net losscash positionrevenueR&DG&A

Risk Factors

High cash burn relative to market cap; $242M net loss in 2025 raises sustainability concerns if future financing is needed.
Loss of collaboration revenue stream — $10M in 2024 vs. zero in 2025 — with no near-term replacement.
Heavy reliance on future milestone and royalty payments from Boehringer Ingelheim, which are uncertain.

Market Snapshot

Exchange

Nasdaq

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3260828

3 reports for SRZN

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for SRZN — sortable, filterable
	Type				Now
May 4, 2026 5w ago	Insider Cluster NEUTRAL ★ 2/10	$32.07 $24.71	▼ −22.95%	▼ −28.59%	$20.69 (−35.48%)
Mar 23, 2026 11w ago	S-3 BEARISH ★ 7/10	$25.00 $33.03	▼ −32.12%	▼ −23.22%	$20.69 (+17.24%)
Mar 23, 2026 11w ago	Press Release MIXED ★ 6/10	$25.00 $33.03	▲ +32.12%	▲ +23.22%	$20.69 (−17.24%)

US Market Status

Market Closed — Opens in 6h 36m

Related Tickers

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access